Form 4: Summit Therapeutics Director Granted Stock Options

Summit Therapeutics director Alessandra Cesano was granted 38,219 stock options with an exercise price of $17.52, including options in lieu of retainer fees.

Summary

• Alessandra Cesano, a director at Summit Therapeutics Inc. (SMMT), was granted stock options.
• The earliest transaction date reported is January 2, 2026.
• A stock option to buy 35,000 shares of common stock was granted with an exercise price of $17.52.
• This option vests in four quarterly installments on March 31, June 30, September 30, and December 31 of the grant year, contingent on continued service as a non-salaried director.
• Another stock option to buy 3,219 shares of common stock was granted with an exercise price of $17.52.
• This second option was issued pursuant to the issuer's Director Retainer Option Election Plan in lieu of $28,200 in retainer fees.
• This option also vests in four quarterly installments on March 31, June 30, September 30, and December 31 following election, contingent on continued service as a non-salaried director.
• Both options have an expiration date of January 2, 2036.
• Following these transactions, Alessandra Cesano beneficially owns 38,219 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The filing reports a routine grant of stock options to a director, which is a standard compensation practice. It aligns the director's interests with shareholders and conserves cash, indicating a stable approach to governance and compensation.

Positives

• Granting of stock options to Director Alessandra Cesano aligns her interests with those of shareholders, incentivizing long-term performance.
• The use of options in lieu of retainer fees ($28,200) conserves cash for the company.

Negatives

• No direct negatives are apparent from this routine compensation filing.

Risks

• NA

Future Outlook

The filing details future vesting schedules for the granted stock options, which will occur in quarterly installments on March 31, June 30, September 30, and December 31 of the grant year, or following election, subject to the director's continued service.

Management Comments

• NA

Industry Context

Granting stock options to non-executive directors is a common practice in the biotechnology and pharmaceutical industry to align director incentives with long-term shareholder value and to conserve cash.

Comparison to Industry Standards

• The practice of granting stock options as part of director compensation, including in lieu of cash fees, is a standard corporate governance practice across many industries, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule (quarterly over one year) is typical for director equity grants, ensuring continued engagement.

Corporate Governance

Related Party Transactions

• The grant of 3,219 stock options to Director Alessandra Cesano was in lieu of $28,200 in retainer fees, as per the Director Retainer Option Election Plan.

Stakeholder Impact

• Shareholders: Interests are aligned with the director through equity compensation, potentially leading to better long-term decision-making.
• Company: Cash is conserved by issuing options instead of cash for retainer fees.

Next Steps

• Vesting of 35,000 stock options in four quarterly installments on March 31, June 30, September 30, and December 31 of 2026.
• Vesting of 3,219 stock options in four quarterly installments on March 31, June 30, September 30, and December 31 following election.

Key Dates

Recommendation

This Form 4 filing details a routine grant of stock options to a director as part of their compensation package, including options in lieu of cash retainer fees. While it aligns director incentives with shareholder interests and conserves cash, it does not present new information that would fundamentally alter the investment thesis for Summit Therapeutics. Therefore, a 'hold' recommendation is appropriate as this filing does not provide a basis for a change in investment strategy.

Keywords

SMMT, Summit Therapeutics, stock options, director compensation, insider transaction, equity grant, Form 4